Literature summary for 3.4.21.77 extracted from

Catalona, W.J.; Partin, A.W.; Sanda, M.G.; Wei, J.T.; Klee, G.G.; Bangma, C.H.; Slawin, K.M.; Marks, L.S.; Loeb, S.; Broyles, D.L.; Shin, S.S.; Cruz, A.B.; Chan, D.W.; Sokoll, L.J.; Roberts, W.L.; van Schaik, R.H.; Mizrahi, I.A.
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range (2011), J. Urol., 185, 1650-1655.

Application

Application	Comment	Organism
medicine	evaluation of the use of proPSA, free PSA, and PSA to enhance specificity for detecting overall and high-grade prostate cancer. Study on men in a prospective multi-institutional trial with no history of prostate cancer shows that prostate health index Phi may be useful in prostate cancer screening to reduce unnecessary biopsies in men age over 50 years with PSA values of 2-10 ng/ml and negative digital rectal examination findings, with minimal loss in sensitivity	Homo sapiens

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue	Comment	Organism	Textmining
prostate	-	Homo sapiens	-
serum	-	Homo sapiens	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)